The coronavirus pandemic is likely to last as long as two years and will not be properly controlled until two-thirds of the world’s populations have become immune.

US Secretary of State Mike Pompeo claimed that there is evidence the COVID-19 coronavirus was created in a lab, despite US intelligence officials stating it probably occurred naturally.

British scientists are testing an experimental drug to help some of society’s most vulnerable fight off the COVID-19 coronavirus.

Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one of the only therapies to do so at this early stage of the pandemic. Now, the FDA has invoked its Emergency Use Authorization powers to approve the drug for the treatment of patients hospitalised with the novel coronavirus.

A new online reporting site has been launched by the Medicines and Healthcare products Regulatory Agency’s (MHRA) to track potential side-effects arising from the use of any therapies used to treat COVID-19, in a bid to build a knowledge base around safe treatment of the pandemic disease.

A French patient who suffered from pneumonia in December actually had COVID-19, it has been revealed.

Ousted Director of the Biomedical Advanced Research and Development Authority (BARDA), Dr Rick Bright, alleges the Trump administration ignored warnings about the severity of the coronavirus.

Vaccines and treatments for COVID-19 continue to dominate the news, as two studies reveal "positive" data for Gilead's remdesivir in hospitalised coronavirus patients while Lonza and Moderna have entered an agreement to mass produce a vaccine.

Two studies from the UK and US have identified hundreds of mutations in COVID-19, which could cause problems for the development of a vaccine.

Britain has become the first European nation to pass 30,000 deaths from the coronavirus, putting it only behind the US as the worst hit country in the world in terms of fatalities.

A recent report from the Office of National Statistics (ONS) has shown that black people in Britain are four times more likely to die from the COVID-19 coronavirus than white Britons.

New crop of data suggests drug can speed recovery from COVID-19

Psoriasis therapy may be a potential treatment for COVID-19

Ramps up capacity for testing across the country

Drug could be ready for clinical trials before the end of the year

Experts says $20bn needed to vaccinate global population

Results could unlock another big market for the company’s star drug

Two antibody cocktails for COVID-19 could be available as early as this autumn

The U.S. Food and Drug Administration posted a photo:

This product is promoted with unapproved claims to prevent, treat, mitigate, or cure COVID-19. FDA warns consumers to avoid unproven and potentially unsafe products. See the Warning Letter for more information:

www.fda.gov/inspections-compliance-enforcement-and-crimin...

More information is available at www.fda.gov/consumers/health-fraud-scams/fraudulent-coron...

Photo by FDA's Office of Regulatory Affairs, Health Fraud Branch

This photo is free of all copyright restrictions and available for use and redistribution without permission. Credit to FDA's Office of Regulatory Affairs, Health Fraud Branch is appreciated but not required.

Click to view a price quote on AGN.

The ongoing spread of COVID-19 in Russia is leading to shortages of drugs against orphan diseases in…

A collaboration in COVID-19 between immunology specialist Vir Biotechnology and Alnylam Pharmaceuticals…

India’s Lupin has announced positive top-line results from its pivotal Phase III clinical trial to…

A new collaboration between Shanghai’s Junshi Biosciences and Eli Lilly will seek to develop novel…

Specialty chemicals company Evonik has kicked off a major expansion project at two German facilities,…

The COVID-19 pandemic did not stop China from launching its national blockchain-based service network…

As with other companies, US drug giant Pfizer and its German partner BioNTech are moving forward their…

Investors in Regeneron could afford a rare smile in these difficult times, as the company’s first quarter…

California’s Gilead Sciences has outlined a plan to ramp up production of newly USA-approved COVID-19…

Following a couple of active M&A years, USA-based Alexion Pharmaceuticals has now reached a definitive…

US drugmaker Alexion Pharmaceuticals fared better in its revenue and adjusted earnings figures in the…

Mark Brewer, who heads up the life sciences team at UK broker and M&A advisory company, finnCap, gives…

The fallout from the COVID-19 pandemic has been challenging for many life sciences companies due to a…

As had been widely expected, Gilead Sciences on Thursday announced that the Japanese Ministry of Health,…

The US Food and Drug Administration has granted accelerated approval for Retevmo (selpercatinib) capsules…

Gilead Sciences scored a massive win earlier this week with its first positive data readout for investigational candidate remdesivir in treating patients with severe COVID-19. Gilead already has its own supply of the drug humming in anticipation of high demand, but opportunities are out there for a partner to join in. 

Days after U.S. officials reported the first positive controlled data for Gilead's remdesivir in COVID-19, the FDA has given the drug an emergency use authorization.

Roche scored a major win with the FDA's backing for its COVID-19 antibody tests last week in a field marked by products of questionable quality. Now, to cover its booming production goals, Roche plans to infuse nearly half-a-billion dollars into its German manufacturing facility. 

While Gilead has yet to present a marketing plan for remdesivir—much less a price—ICER figures the COVID-19 drug could be cost-effective at up to $4,460 per patient. That means it could easily rake in blockbuster sales this year, at least theoretically.